Cooper Companies 将来の成長

Future 基準チェック /46

Cooper Companies利益と収益がそれぞれ年間23%と7%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に10% 24.1%なると予測されています。

主要情報

23.0%

収益成長率

24.1%

EPS成長率

Medical Equipment 収益成長	22.6%
収益成長率	7.0%
将来の株主資本利益率	10.0%
アナリストカバレッジ	Good
最終更新日	14 Nov 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

LSE:0I3I - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
10/31/2027	4,907	882	1,012	1,429	2
10/31/2026	4,473	778	703	1,051	13
10/31/2025	4,201	645	626	944	18
10/31/2024	3,903	447	541	816	17
7/31/2024	3,804	359	189	615	N/A
4/30/2024	3,732	340	122	550	N/A
1/31/2024	3,666	291	136	564	N/A
10/31/2023	3,593	294	215	608	N/A
7/31/2023	3,514	275	222	564	N/A
4/30/2023	3,427	288	387	685	N/A
1/31/2023	3,380	375	425	693	N/A
10/31/2022	3,308	386	450	692	N/A
7/31/2022	3,219	431	524	736	N/A
4/30/2022	3,139	948	487	696	N/A
1/31/2022	3,029	939	541	757	N/A
10/31/2021	2,923	2,945	524	739	N/A
7/31/2021	2,845	2,916	526	782	N/A
4/30/2021	2,660	2,355	414	671	N/A
1/31/2021	2,465	2,249	207	505	N/A
10/31/2020	2,431	238	176	487	N/A
7/31/2020	2,441	278	180	468	N/A
4/30/2020	2,542	343	234	552	N/A
1/31/2020	2,672	454	459	741	N/A
10/31/2019	2,653	467	421	713	N/A
7/31/2019	2,613	446	499	750	N/A
4/30/2019	2,594	427	561	788	N/A
1/31/2019	2,571	366	523	745	N/A
10/31/2018	2,533	140	-630	669	N/A
7/31/2018	2,443	128	-656	631	N/A
4/30/2018	2,339	131	N/A	551	N/A
1/31/2018	2,230	175	N/A	511	N/A
10/31/2017	2,139	373	N/A	594	N/A
7/31/2017	2,096	345	N/A	588	N/A
4/30/2017	2,055	329	N/A	562	N/A
1/31/2017	2,016	298	N/A	529	N/A
10/31/2016	1,967	274	N/A	510	N/A
7/31/2016	1,904	250	N/A	421	N/A
4/30/2016	1,851	207	N/A	388	N/A
1/31/2016	1,801	194	N/A	401	N/A
10/31/2015	1,797	204	N/A	391	N/A
7/31/2015	1,810	198	N/A	439	N/A
4/30/2015	1,780	241	N/A	450	N/A
1/31/2015	1,758	259	N/A	466	N/A
10/31/2014	1,718	270	N/A	455	N/A
7/31/2014	1,661	296	N/A	453	N/A
4/30/2014	1,640	297	N/A	448	N/A
1/31/2014	1,611	293	N/A	437	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 0I3Iの予測収益成長率 (年間23% ) は貯蓄率 ( 2.1% ) を上回っています。

収益対市場: 0I3Iの収益 ( 23% ) はUK市場 ( 14.8% ) よりも速いペースで成長すると予測されています。

高成長収益: 0I3Iの収益は今後 3 年間で大幅に増加すると予想されています。

収益対市場: 0I3Iの収益 ( 7% ) UK市場 ( 3.6% ) よりも速いペースで成長すると予測されています。

高い収益成長: 0I3Iの収益 ( 7% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 0I3Iの自己資本利益率は、3年後には低くなると予測されています ( 10 %)。

Cooper Companies 将来の成長

Future 基準チェック /46

主要情報

今後の成長に関する最新情報

The Cooper Companies, Inc. Raises Earnings Guidance for the Fourth Quarter and Fiscal Year 2024

The Cooper Companies, Inc. Raises Earnings Guidance for the Fiscal Year 2024

The Cooper Companies, Inc. Raises its Revenue Guidance for the Fiscal Year 2024

The Cooper Companies, Inc. Provides Revenue Guidance for the Fiscal Year 2024

The Cooper Companies, Inc. Updates Revenue Guidance for the Year 2023

The Cooper Companies, Inc. Provides Revenue Guidance for the Year 2023

Recent updates

The Cooper Companies, Inc. to Report Q4, 2024 Results on Dec 05, 2024

Third quarter 2024 earnings released: EPS: US$0.52 (vs US$0.43 in 3Q 2023)

The Cooper Companies, Inc. Raises Earnings Guidance for the Fourth Quarter and Fiscal Year 2024

The Cooper Companies, Inc. to Report Q3, 2024 Results on Aug 28, 2024

Second quarter 2024 earnings released: EPS: US$0.45 (vs US$0.20 in 2Q 2023)

The Cooper Companies, Inc. Raises Earnings Guidance for the Fiscal Year 2024

The Cooper Companies, Inc. to Report Q2, 2024 Results on May 30, 2024

First quarter 2024 earnings released: EPS: US$0.41 (vs US$0.43 in 1Q 2023)

The Cooper Companies, Inc. Raises its Revenue Guidance for the Fiscal Year 2024

Girard Sharp LLP and Sauder Schelkopf LLC Files Lawsuit Against Coopersurgical, Inc. and the Cooper Companies, Inc

The Cooper Companies, Inc. Announces Resignation of Gary S. Petersmeyer from Board of Directors

Slater Vecchio LLP Files Class Action Lawsuit Against LifeGroup Global LLC, The Cooper Companies Inc, CooperSurgical Inc, and CooperSurgical Canada Inc

The Cooper Companies, Inc. to Report Q1, 2024 Results on Feb 29, 2024

The Cooper Companies, Inc., Annual General Meeting, Mar 19, 2024

The Cooper Companies, Inc. Announces Retirement of Gary S. Petersmeyer as Director

Full year 2023 earnings released: EPS: US$5.91 (vs US$7.83 in FY 2022)

The Cooper Companies, Inc. Provides Revenue Guidance for the Fiscal Year 2024

CooperCompanies Appoints Lawrence E. Kurzius to Board of Directors, Effective December 1, 2023

Now 20% undervalued after recent price drop

Now 22% undervalued after recent price drop

The Cooper Companies, Inc. to Report Q4, 2023 Results on Dec 07, 2023

The Cooper Companies, Inc. (NasdaqGS:COO) acquired Bakri Postpartum Balloon, Cervical Ripening Balloon, Doppler Blood Flow Monitor portfolio and gynecology surgery markets of Cook Medical Incorporated for $300 million.

Now 21% undervalued

The Cooper Companies, Inc. Updates Revenue Guidance for the Year 2023

Third quarter 2023 earnings released: EPS: US$1.71 (vs US$2.00 in 3Q 2022)

Upcoming dividend of US$0.03 per share

The Cooper Companies, Inc. Provides Revenue Guidance for the Year 2023

Second quarter 2023 earnings released: EPS: US$0.80 (vs US$2.57 in 2Q 2022)

Senior VP & Chief Accounting Officer recently sold US$370k worth of stock

President of CooperVision recently sold US$414k worth of stock

First quarter 2023 earnings released: EPS: US$1.70 (vs US$1.93 in 1Q 2022)

The Cooper Companies, Inc. to Report Q1, 2023 Results on Mar 02, 2023

Upcoming dividend of US$0.03 per share

The Cooper Companies, Inc., Annual General Meeting, Mar 15, 2023

CooperCompanies Declares Cash Dividend, Payable on February 10, 2023

Full year 2022 earnings released: EPS: US$7.76 (vs US$59.85 in FY 2021)

The Cooper Companies, Inc. Initiates Earnings Guidance for the Fiscal Year 2023

Investor sentiment improved over the past week

The Cooper Companies, Inc. to Report Q4, 2022 Results on Dec 08, 2022

the Cooper Companies, Inc. Appoints Cynthia Lucchese to Board of Directors

the Cooper Companies, Inc. Updates Revenue Guidance for Fourth Quarter and Full year 2022

Third quarter 2022 earnings released: EPS: US$1.98 (vs US$12.49 in 3Q 2021)

the Cooper Companies, Inc. Updates Revenue Guidance for Fourth Quarter and Full Year Year 2022

CooperCompanies Appoints Nicholas Khadder as Its General Counsel and Corporate Secretary

The Cooper Companies, Inc. to Report Q3, 2022 Results on Aug 31, 2022

Upcoming dividend of US$0.03 per share

CooperCompanies Declares Semi-Annual Cash Dividend, Payable on August 11, 2022

The Cooper Companies, Inc. Provides Consolidated Earnings Guidance for the Third Quarter, Fourth Quarter and Full Year of Fiscal 2022

Second quarter 2022 earnings released: EPS: US$2.55 (vs US$2.39 in 2Q 2021)

Independent Director recently sold US$123k worth of stock

The Cooper Companies, Inc. Provides Revenue Earnings Guidance for the Fiscal Year 2022

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

The Cooper Companies, Inc. (NYSE:COO) signed a binding letter of intent to acquire Reproductive Health Business of Cook Medical for $880 million.

The Cooper Companies, Inc. to Report Q1, 2022 Results on Mar 03, 2022

Insufficient new directors

Inaugural dividend of US$0.03 per share

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

The Cooper Companies, Inc. Provides Earnings Guidance for the Fiscal Year 2022

Independent Director recently sold US$201k worth of stock

The Cooper Companies, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of Fiscal 2021

Third quarter 2021 earnings released: EPS US$12.37 (vs US$1.12 in 3Q 2020)

CooperCompanies Announces MiSight® Approval from Chinese National Medical Products Administration

Inaugural dividend of US$0.03 per share

Independent Director recently sold US$165k worth of stock

The Cooper Companies, Inc.(NYSE:COO) dropped from Russell 1000 Growth-Defensive Index

Second quarter 2021 earnings released: EPS US$2.36 (vs US$0.23 in 2Q 2020)

the Cooper Companies, Inc. Provides Earnings Guidance for the Fiscal Year 2021

First quarter 2021 earnings released: EPS US$42.28 (vs US$1.84 in 1Q 2020)

Revenue beats expectations